+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
U.S. Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2025 - 2033- Product Image
U.S. Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2025 - 2033- Product Image
New

U.S. Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2025 - 2033

  • PDF Icon

    Report

  • 120 Pages
  • July 2025
  • Region: United States
  • Grand View Research
  • ID: 6154492
Description Jump to:
The U.S. plasmid DNA manufacturing market size was estimated at USD 803.0 million in 2024 and is projected to reach USD 5.03 billion by 2033, growing at a CAGR of 23.06% from 2025 to 2033. This expansion is driven by increasing demand for gene therapies, DNA vaccines, and other advanced biologics that rely on high-quality plasmid DNA as a foundational component.

Continued investment in biotechnology research and supportive regulatory frameworks are expected to propel market development further over the forecast period.

Rising Prevalence of Genetic Disorders and Cancer

The rising prevalence of genetic disorders and cancer is a major factor driving growth in the U.S. plasmid DNA manufacturing industry. Advances in genetic research have highlighted the role of gene mutations and abnormalities in various diseases, leading to increased development of gene therapies aimed at treating these conditions at their source. Similarly, cancer treatment is increasingly shifting toward personalized and targeted therapies, many of which depend on plasmid DNA as a vector to deliver therapeutic genes or immune modulators. As diagnostic technologies improve and the population ages, more patients are identified as candidates for these innovative therapies, expanding the demand for plasmid DNA.

Moreover, the complex and individualized nature of genetic and cancer therapies requires highly specialized and scalable plasmid DNA manufacturing processes. Biotech companies and research institutions invest heavily in developing flexible production platforms that meet the' rigorous quality standards and volume demands of clinical and commercial applications. This increased focus on precision medicine and tailored treatments further solidifies plasmid DNA's role as a critical component in the evolving landscape of advanced therapeutics, driving sustained market expansion.

U.S. Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the U.S. plasmid DNA manufacturing market report based on grade, development phase, application, and disease:

Grade Outlook (Revenue, USD Million, 2021 - 2033)

  • R&D Grade
  • Viral Vector Development
  • AAV
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Others
  • mRNA Development
  • Antibody Development
  • DNA Vaccine Development
  • Others
  • GMP Grade

Development Phase Outlook (Revenue, USD Million, 2021 - 2033)

  • Pre-Clinical Therapeutics
  • Clinical Therapeutics
  • Marketed Therapeutics

Application Outlook (Revenue, USD Million, 2021 - 2033)

  • DNA Vaccines
  • Cell & Gene Therapy
  • Immunotherapy
  • Others

Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Infectious Disease
  • Cancer
  • Genetic Disorder
  • Others

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Grade
1.2.2. Development Phase
1.2.3. Application
1.2.4. Disease
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.9.1. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Increasing number of patients opting for gene therapy
3.3.2. Robust pipeline for gene therapies
3.3.3. Highly competitive market and various strategies undertaken by market players
3.3.4. Increasing demand for plasmid DNA in various medical therapies
3.4. Market Restraint Analysis
3.4.1. Regulatory, scientific, and ethical challenges associated with gene therapy
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
Chapter 4. Grade Business Analysis
4.1. Segment Dashboard
4.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
4.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
4.4. R&D Grade
4.4.1. R&D Grade Market, 2021 - 2033 (USD Million)
4.4.2. Viral Vector Development
4.4.2.1. Viral Vector Development Market, 2021 - 2033 (USD Million)
4.4.2.2. AAV
4.4.2.2.1. AAV Market, 2021 - 2033 (USD Million)
4.4.2.3. Lentivirus
4.4.2.3.1. Lentivirus Market, 2021 - 2033 (USD Million)
4.4.2.4. Adenovirus
4.4.2.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
4.4.2.5. Retrovirus
4.4.2.5.1. Retrovirus Market, 2021 - 2033 (USD Million)
4.4.2.6. Others
4.4.2.6.1. Others Market, 2021 - 2033 (USD Million)
4.4.3. mRNA Development
4.4.3.1. mRNA Development Market, 2021 - 2033 (USD Million)
4.4.4. Antibody Development
4.4.4.1. Antibody Development Market, 2021 - 2033 (USD Million)
4.4.5. DNA Vaccine Development
4.4.5.1. DNA Vaccine Development Market, 2021 - 2033 (USD Million)
4.4.6. Others
4.4.6.1. Others Market, 2021 - 2033 (USD Million)
4.5. GMP Grade
4.5.1. GMP Grade Market, 2021 - 2033 (USD Million)
Chapter 5. Development Phase Business Analysis
5.1. Segment Dashboard
5.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
5.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2021 to 2033 (USD Million)
5.4. Pre-Clinical Therapeutics
5.4.1. Pre-Clinical Therapeutics Market, 2021 - 2033 (USD Million)
5.5. Clinical Therapeutics
5.5.1. Clinical Therapeutics Market, 2021 - 2033 (USD Million)
5.6. Marketed Therapeutics
5.6.1. Marketed Therapeutics Market, 2021 - 2033 (USD Million)
Chapter 6. Application Business Analysis
6.1. Segment Dashboard
6.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
6.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. DNA Vaccines
6.4.1. DNA Vaccines Market, 2021 - 2033 (USD Million)
6.5. Cell & Gene Therapy
6.5.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
6.6. Immunotherapy
6.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
6.7. Others
6.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Disease Business Analysis
7.1. Segment Dashboard
7.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
7.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
7.4. Infectious Disease
7.4.1. Infectious Disease Market, 2021 - 2033 (USD Million)
7.5. Cancer
7.5.1. Cancer Market, 2021 - 2033 (USD Million)
7.6. Genetic Disorder
7.6.1. Genetic Disorder Market, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Categorization
8.2. Company Market Position Analysis, 2024
8.3. Participant’s Overview
8.3.1. Charles River Laboratories
8.3.1.1. Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Danaher (Aldevron)
8.3.2.1. Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. VGXI, Inc.
8.3.3.1. Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Kaneka Corp.
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Lonza
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Nature Technology
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Cell and Gene Therapy Catapult
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Eurofins Genomics
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Luminous BioSciences, LLC
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Akron Biotech
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
List of Tables
Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 U.S. Plasmid DNA Manufacturing Market by Grade, 2021 - 2033 (USD Million)
Table 4 U.S. Plasmid DNA Manufacturing Market by Development Phase, 2021 - 2033 (USD Million)
Table 5 U.S. Plasmid DNA Manufacturing Market by Application, 2021 - 2033 (USD Million)
Table 6 U.S. Plasmid DNA Manufacturing Market by Disease, 2021 - 2033 (USD Million)
Table 7 Participant’s Overview
List of Figures
Fig. 1 U.S. plasmid DNA manufacturing market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Market outlook
Fig. 8 Segment snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Parent market outlook
Fig. 11 U.S. plasmid DNA manufacturing market driver analysis
Fig. 12 U.S. plasmid DNA manufacturing market restraint analysis
Fig. 13 U.S. plasmid DNA manufacturing market: Porter's analysis
Fig. 14 U.S. plasmid DNA manufacturing market: PESTEL analysis
Fig. 15 U.S. plasmid DNA manufacturing market: Grade outlook and key takeaways
Fig. 16 U.S. plasmid DNA manufacturing market: Grade movement analysis
Fig. 17 U.S. R&D grade market, 2021 - 2033 (USD Million)
Fig. 18 U.S. viral vector development market, 2021 - 2033 (USD Million)
Fig. 19 U.S. mRNA development market, 2021 - 2033 (USD Million)
Fig. 20 U.S. antibody development market, 2021 - 2033 (USD Million)
Fig. 21 U.S. DNA vaccine development market, 2021 - 2033 (USD Million)
Fig. 22 U.S. others market, 2021 - 2033 (USD Million)
Fig. 23 U.S. AAV market, 2021 - 2033 (USD Million)
Fig. 24 U.S. lentivirus market, 2021 - 2033 (USD Million)
Fig. 25 U.S. adenovirus market, 2021 - 2033 (USD Million)
Fig. 26 U.S. retrovirus market, 2021 - 2033 (USD Million)
Fig. 27 U.S. GMP grade market, 2021 - 2033 (USD Million)
Fig. 28 U.S. others market, 2021 - 2033 (USD Million)
Fig. 29 U.S. plasmid DNA manufacturing market: Development phase outlook and key takeaways
Fig. 30 U.S. plasmid DNA manufacturing market: Development phase movement analysis
Fig. 31 U.S. pre-clinical therapeutics market, 2021 - 2033 (USD Million)
Fig. 32 U.S. clinical therapeutics market, 2021 - 2033 (USD Million)
Fig. 33 U.S. marketed therapeutics market, 2021 - 2033 (USD Million)
Fig. 34 U.S. plasmid DNA manufacturing market: Application outlook and key takeaways
Fig. 35 U.S. plasmid DNA manufacturing market: Application movement analysis
Fig. 36 U.S. DNA vaccines market, 2021 - 2033 (USD Million)
Fig. 37 U.S. cell & gene therapy market, 2021 - 2033 (USD Million)
Fig. 38 U.S. immunotherapy market, 2021 - 2033 (USD Million)
Fig. 39 U.S. others market, 2021 - 2033 (USD Million)
Fig. 40 U.S. plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 41 U.S. plasmid DNA manufacturing market: Disease movement analysis
Fig. 42 U.S. infectious disease market, 2021 - 2033 (USD Million)
Fig. 43 U.S. cancer market, 2021 - 2033 (USD Million)
Fig. 44 U.S. genetic disorder market, 2021 - 2033 (USD Million)
Fig. 45 U.S. others market, 2021 - 2033 (USD Million)

Companies Mentioned

  • Charles River Laboratories
  • VGXI, Inc.
  • Danaher (Aldevron)
  • Kaneka Corp.
  • Nature Technology
  • Cell and Gene Therapy Catapult
  • Eurofins Genomics
  • Lonza
  • Luminous BioSciences, LLC
  • Akron Biotech

Table Information

Report AttributeDetails
No. of Pages120
PublishedJuly 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 0.8 Billion
Forecasted Market Value ( USD ) by 2033 $ 5.03 Billion
Compound Annual Growth Rate23.0%
Regions CoveredUnited States
No. of Companies Mentioned10

Related Topics

Related Reports

Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033 - Product Image

Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • Report
  • 179 Pages
  • Global
From
Plasmid Purification Market Size, Share & Trends Analysis Report By Product & Service, By Grade (Molecular Grade, Transfection Grade), By Application (Cloning & Protein Expression, Transfection & Gene Editing), By End-use, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Plasmid Purification Market Size, Share & Trends Analysis Report By Product & Service, By Grade (Molecular Grade, Transfection Grade), By Application (Cloning & Protein Expression, Transfection & Gene Editing), By End-use, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 120 Pages
  • Global
From
Plasmid DNA Contract Manufacturing Market Size, Share & Trends Analysis Report By Application (Cell & Gene Therapy, Immunotherapy), By Therapeutic Area (Cancer, Infectious Diseases), By End-user, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Plasmid DNA Contract Manufacturing Market Size, Share & Trends Analysis Report By Application (Cell & Gene Therapy, Immunotherapy), By Therapeutic Area (Cancer, Infectious Diseases), By End-user, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 275 Pages
  • Global
From
U.S. DNA Manufacturing Market Size, Share & Trends Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade (GMP & R&D), By Application (Cell & Gene Therapy, Vaccines, Oligonucleotide-based Drugs), By End-use, And Segment Forecasts, 2025 - 2030 - Product Image

U.S. DNA Manufacturing Market Size, Share & Trends Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade (GMP & R&D), By Application (Cell & Gene Therapy, Vaccines, Oligonucleotide-based Drugs), By End-use, And Segment Forecasts, 2025 - 2030

  • Report
  • 90 Pages
  • United States
From
Viral Vector and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector Type (AAV, Lentivirus), Workflow, Application, End-use, Disease, Region, and Segment Forecasts, 2024-2030 - Product Image

Viral Vector and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector Type (AAV, Lentivirus), Workflow, Application, End-use, Disease, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.